H3F3A is altered in 72.55% of diffuse intrinsic pontine glioma patients with H3F3A K28M present in 72.55% of all diffuse intrinsic pontine glioma patients [4].

H3F3A K28M is an inclusion criterion in 6 clinical trials for diffuse intrinsic pontine glioma, of which 6 are open and 0 are closed. Of the trials that contain H3F3A K28M and diffuse intrinsic pontine glioma as inclusion criteria, 4 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open) [5].

H3F3A is altered in 72.55% of diffuse midline glioma, H3 K27M-mutant patients with H3F3A K28M present in 72.55% of all diffuse midline glioma, H3 K27M-mutant patients [4].

H3F3A K28M is an inclusion criterion in 6 clinical trials for diffuse midline glioma, H3 K27M-mutant, of which 6 are open and 0 are closed. Of the trials that contain H3F3A K28M and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 5 are phase 1 (5 open) and 1 is phase 1/phase 2 (1 open) [5].

H3F3A is altered in 3.95% of malignant glioma patients with H3F3A K28M present in 2.82% of all malignant glioma patients [4].

H3F3A K28M is an inclusion criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain H3F3A K28M and malignant glioma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [5].

H3F3A is altered in 3.86% of diffuse glioma patients with H3F3A K28M present in 2.92% of all diffuse glioma patients [4].

H3F3A K28M is an inclusion criterion in 3 clinical trials for diffuse glioma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A K28M and diffuse glioma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [5].

H3F3A is altered in 2.72% of anaplastic astrocytoma patients with H3F3A K28M present in 1.81% of all anaplastic astrocytoma patients [4].

H3F3A K28M is an inclusion criterion in 3 clinical trials for anaplastic astrocytoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A K28M and anaplastic astrocytoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [5].

H3F3A is altered in 2.35% of glioblastoma patients with H3F3A K28M present in 1.17% of all glioblastoma patients [4].

H3F3A K28M is an inclusion criterion in 3 clinical trials for glioblastoma, of which 3 are open and 0 are closed. Of the trials that contain H3F3A K28M and glioblastoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 3 (1 open) [5].

H3F3A is altered in 11.8% of high-grade glioma, NOS patients with H3F3A K28M present in 10.11% of all high-grade glioma, NOS patients [4].

H3F3A K28M is an inclusion criterion in 2 clinical trials for high-grade glioma, NOS, of which 2 are open and 0 are closed. Of the trials that contain H3F3A K28M and high-grade glioma, NOS as inclusion criteria, 2 are phase 1 (2 open) [5].

H3F3A is altered in 3.69% of glioma patients with H3F3A K28M present in 2.82% of all glioma patients [4].

H3F3A K28M is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain H3F3A K28M and glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

H3F3A is altered in 1.23% of medulloblastoma patients with H3F3A K28M present in 0.61% of all medulloblastoma patients [4].

H3F3A K28M is an inclusion criterion in 2 clinical trials for medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain H3F3A K28M and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open) [5].

H3F3A K28M is an inclusion criterion in 2 clinical trials for atypical teratoid/rhabdoid tumor, of which 2 are open and 0 are closed. Of the trials that contain H3F3A K28M and atypical teratoid/rhabdoid tumor as inclusion criteria, 2 are phase 1 (2 open) [5].

H3F3A K28M is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain H3F3A K28M and ependymoma as inclusion criteria, 2 are phase 1 (2 open) [5].

H3F3A is altered in 3.49% of malignant central nervous system neoplasm patients with H3F3A K28M present in 2.65% of all malignant central nervous system neoplasm patients [4].

H3F3A K28M is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A is altered in 2.0% of ependymal tumor patients with H3F3A K28M present in 0.67% of all ependymal tumor patients [4].

H3F3A K28M is an inclusion criterion in 1 clinical trial for ependymal tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and ependymal tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A is altered in 0.86% of central nervous system embryonal neoplasm patients with H3F3A K28M present in 0.43% of all central nervous system embryonal neoplasm patients [4].

H3F3A K28M is an inclusion criterion in 1 clinical trial for central nervous system embryonal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A is altered in 3.57% of anaplastic ependymoma patients [4].

H3F3A K28M is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for anaplastic oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and anaplastic oligoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for central nervous system ganglioneuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for central nervous system neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for fibrillary astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and fibrillary astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for gliomatosis cerebri, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and gliomatosis cerebri as inclusion criteria, 1 is phase 3 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for malignant central nervous system germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and malignant central nervous system germ cell tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for malignant primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and malignant primary brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for medulloblastoma, non-WNT/non-SHH, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for medulloblastoma, SHH-activated, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and medulloblastoma, SHH-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for medulloblastoma, WNT-activated, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A K28M is an inclusion criterion in 1 clinical trial for medulloepithelioma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

H3F3A is altered in 0.25% of primitive neuroectodermal tumor patients [4].

H3F3A K28M is an inclusion criterion in 1 clinical trial for primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A K28M and primitive neuroectodermal tumor as inclusion criteria, 1 is phase 1 (1 open) [5].